01—Abstract
Summary
Summary of the 10-K filed March 15, 2013. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. (ABBV) filed its 2013 10-K report, detailing its first full year as an independent entity following its spin-off from Abbott Laboratories on January 1, 2013.
The company is a research-based biopharmaceutical firm focused on developing and marketing advanced therapies for complex diseases. Its product portfolio is heavily reliant on HUMIRA, which accounted for approximately 50% of total sales in 2012 ($9.3 billiona), and is expected to drive significant future growth. AbbVie's strategy centers on expanding HUMIRA's indications, advancing its robust pipeline of over 20 compounds in Phase II or III development across key therapeutic areas like immunology, oncology, and neuroscience, and increasing its presence in emerging markets.
The report highlights AbbVie's strong financial performance despite the ongoing costs and complexities associated with operating as a standalone company. Key financial metrics include net sales of $18.38 billionb and net earnings of $5.275 billion for the year ended December 31, 2012.
The company has also secured a significant debt facility and has a clear dividend policy in place. Investors should note the upcoming patent expirations for key products, particularly HUMIRA's composition of matter patent in December 2016, as a potential future challenge, although the company's pipeline and ongoing R&D efforts aim to mitigate these risks.
02—Key points
Key Highlights
- AbbVie separated from Abbott Laboratories on January 1, 2013, becoming an independent, publicly traded company.
- HUMIRA was the dominant product, generating $9.3 billion in sales in 2012, representing approximately 50% of total net sales.
- The company reported net sales of $18.38 billion and net earnings of $5.275 billion for the fiscal year ended December 31, 2012.
- AbbVie has a strong pipeline with over 20 compounds in Phase II or Phase III development across various therapeutic areas.
- Significant R&D investment is ongoing, with approximately 15% of net sales dedicated to research and development.
- The company faced generic competition for TriCor in late 2012 and anticipates similar pressures for Niaspan and TRILIPIX in the near future.
- AbbVie expects to pay a regular cash dividend of $1.60 per share annually, starting in February 2013.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2012, AbbVie Inc. kept $0.29.
- Revenue$18.38B100.0%
- Cost of revenue−$4.51B24.5%
- Gross profit$13.87B75.5%
- Operating costs−$8.05B43.8%
- Operating income$5.82B31.6%
- Interest, other & tax−$542.0M2.9%
- Net income$5.28B28.7%
Where FY2012 revenue went
$18.38B- Net income: $5.28B, 29% of revenue
- SG&A: $4.99B, 27% of revenue
- Cost of revenue: $4.51B, 25% of revenue
- Other operating costs: $3.07B, 17% of revenue
- Interest, other & tax: $542.0M, 2.9% of revenue
Kept 29% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2012filed March 15, 2013Financial Statements
FY2012 against FY2011
| Line item | FY2012FY2011 | Change |
|---|---|---|
| Revenue | $18.38B$17.44B | +5.4% |
| Cost of Revenue | $4.51B$4.64B | −2.8% |
| Gross Profit | $13.87B$12.80B | +8.3% |
| SG&A Expenses | $4.99B$5.89B | −15.4% |
| Operating Expenses | $12.56B$13.82B | −9.1% |
| Operating Income | $5.82B$3.62B | +60.7% |
| Interest Expense | $104.00M— | — |
| Net Income | $5.28B$3.43B | +53.7% |
| EPS (Basic) | $3.35$2.18 | +53.7% |
| EPS (Diluted) | $3.35$2.18 | +53.7% |
| Shares Outstanding (Basic) | 1.58B1.58B | 0.0% |
| Shares Outstanding (Diluted) | 1.58B1.58B | 0.0% |
05—Questions
Frequently Asked Questions
What was AbbVie's primary revenue driver in 2012?
AbbVie's primary revenue driver was HUMIRA, which generated $9.3 billion in worldwide sales, accounting for approximately 50% of the company's total net sales in 2012.
What are the key strategic priorities for AbbVie moving forward?
AbbVie's key strategic priorities include maximizing its existing portfolio through new indications and geographic expansion, advancing its pipeline of new medicines, growing its presence in emerging markets, and managing its product portfolio to maximize value.
What are the major risks highlighted by AbbVie regarding its business?
Key risks identified include the expiration or loss of patent protection for major products like HUMIRA, the potential impact of biosimilars, the success of research and development efforts in bringing new products to market, competition from other pharmaceutical companies, and the impact of government regulations and pricing pressures.
How did the separation from Abbott Laboratories affect AbbVie's financial reporting?
AbbVie's financial statements were presented on a standalone basis, derived from Abbott's consolidated records. The company incurred costs associated with establishing its independent operations and infrastructure, which were not always fully reflected in the historical allocations from Abbott, potentially impacting comparability to future standalone performance.
06—Continue